ClinicalTrials.gg
RecruitingNCT05918445Updated Dec 5, 2024

PM8002 in the Treatment of Patients With Advanced Solid Tumors

A Phase 1/2 interventional study of PM8002 in Malignant Neoplasm, sponsored by Biotheus Inc.. Recruiting at 48 sites in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2024-12-05.

Sponsored by Biotheus Inc. (part of BioNTech SE) · Phase 1/2, Interventional, and Treatment

From the registry’s dates

  • Primary completion was expected by Nov 2025, 11 months ago, but the record still lists the study as recruiting.
  • Registered 2 years 2 months after the study started (first participant enrolled Mar 2021, registered May 2023).
  • Started Mar 2021; still recruiting 5 years 8 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
380
Allocation
Not applicable
Ages
18 Years to 75 Years
Sex
All
01

Study summary

This study is to characterize the safety, tolerability, pharmacokinetics (PK), immunogenicity, pharmacodynamics (PD) and anti-tumor activity of PM8002, a PD-L1/VEGF bispecific antibody, as a single agent in adult subjects with advanced solid tumors.

02

Conditions studied

  • Malignant Neoplasm

Browse trials for

03

In context

Neoplasms

10,826 studies on the registry are indexed under Neoplasms; 2,325 are open to participants now.

This study's planned enrollment of 380 is above the median of 60 across 7,706 interventional studies indexed under Neoplasms.

Browse Neoplasms studies →

Lead sponsor

Biotheus Inc. is the lead sponsor of 18 studies on the registry; 8 are open to participants now.

First submitted before Biotheus Inc. became part of BioNTech SE.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Voluntary participation in clinical study; fully understand the study and sign voluntarily; willing to follow and able to complete all test procedures;
  2. Male or female aged 18 to 75 years;
  3. Patients with malignant tumor confirmed by histology or cytology;
  4. The toxicity of previous anti-tumor therapy has not been alleviated;
  5. Adequate organ function;
  6. score was 0-1;
  7. Expected survival >=12 weeks;
  8. According to 1.1 criteria, at least 1 that has not been previously treated locally.

Exclusion criteria

Exclusion Criteria:

  1. History of severe allergic disease, severe allergy to drugs or known allergy to any component of the drug in this study;
  2. Evidence of major coagulopathy or other obvious risk of bleeding;
  3. Patients are experiencing a clear interstitial lung disease or non-infectious pneumonia, unless it is caused by local radiotherapy;
  4. Patients with uncontrolled should be excluded from this clinical trial;
  5. Patients ever experienced other active malignant tumors within 5 years prior to the study treatment;
  6. Prior allogeneic organ transplantation or hematopoietic stem cell transplantation;
  7. Known history of alcohol abuse, psychotropic drug abuse or drug abuse;
  8. Syphilis antibody positive;
  9. Patients with active tuberculosis (TB) are excluded;
  10. Pregnant or lactating women;
  11. Other conditions lead to inappropriate to participate in this study as judged by the investigator.
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
380 participants (estimated)

Study arms

  • Experimental
    PM8002

    PM8002 IV every 2 weeks(q2w) or every 3 weeks(q3w)

    Drug: PM8002

Interventions

06

What researchers measure

Primary outcomes

  1. Number of participants with DLTs

    DLTs will be assessed during the dose-escalation phase and are defined as toxicities that meet pre-defined severity criteria and assessed as having a suspected relationship to study drug, and unrelated to disease, disease progression, intercurrent illness, or concomitant medications that occurs within the first cycle (3weeks) of treatment.

    Time frame: During the first three weeks of treatment with PM8002

  2. Treatment related adverse events (TRAEs)

    The incidence and severity of TRAEs graded according to NCI-CTCAE v5.0

    Time frame: Up to 30 days after last treatment

  3. Objective response rate (ORR)

    Objective response rate (ORR) is the proportion of subjects with complete response (CR) or partial response (PR), based on RECIST v1.1.

    Time frame: Up to approximately 2 years

Secondary outcomes

  1. Disease control rate (DCR)

    DCR is defined as the proportion of subjects with CR, PR, or stable disease(SD) based on RECIST v1.1.

    Time frame: Up to approximately 2 years

  2. Duration of response (DoR)

    DoR is defined as the duration from the first documentation of objective response to the first documented disease progression (based on RECIST v1.1). for subjects with no documented disease progression, the deadline is the data of the last examination.

    Time frame: Up to approximately 2 years

  3. Overall survival (OS)

    OS is the time from the date of first dosing date to death due to any cause.

    Time frame: Up to approximately 2 years

  4. Progression-free survival (PFS)

    Progression-free survival is defined as the time from the start of treatment with PM8002 until the first documentation of disease progression or death due to any cause, whichever occurs first.

    Time frame: Up to approximately 2 years

  5. Anti-drug antibody (ADA)

    To evaluate the incidence of ADA to PM8002.

    Time frame: Up to 30 days after last treatment

07

Study locations

48 of 48 sites recruiting
  • Baoji Central Hospital
    Baoji, China
    Recruiting
    • Yaning Zhao · Contact
    • Yaning Zhao · Principal investigator
  • Baoji Central Hospital
    Baoji, China
    Recruiting
    • Gang Wang · Contact
    • Gang Wang · Principal investigator
  • Cancer Hospital Chinese Academy of Medical Sciences
    Beijing, China
    Recruiting
    • Lingying Wu · Contact
    • Lingying Wu · Principal investigator
  • Peking University Cancer Hospital
    Beijing, China
    Recruiting
    • Jun Guo · Contact
    • Jun Guo · Principal investigator
  • Peking University Cancer Hospital
    Beijing, China
    Recruiting
    • Lin Shen · Contact
    • Lin Shen · Principal investigator
  • Jilin Cancer Hospital
    Changchun, China
    Recruiting
    • Yng Cheng · Contact
    • Ying Cheng · Principal investigator
  • The First Hospital of Jilin University
    Changchun, China
    Recruiting
    • Jiuwei Cui · Contact
    • Jiuwei Cui · Principal investigator
  • Changde First People's Hospital
    Changde, China
    Recruiting
    • Tao Wu · Contact
    • Tao Wu · Principal investigator
  • Hunan Provincial People's Hospital
    Changsha, China
    Recruiting
    • Huaxin Duan · Contact
    • Huaxin Duan · Principal investigator
  • The First People's Hospital of Changzhou
    Changzhou, China
    Recruiting
    • Mei Ji · Contact
    • Mei Ji · Principal investigator
  • Chengdu Integrated TCM& Western Medicine Hospital
    Chengdu, China
    Recruiting
    • Ping Li · Contact
    • Ping Li · Principal investigator
  • Sichuan Cancer Hospital
    Chengdu, China
    Recruiting
    • Yongdong Jin · Contact
    • Yongdong Jin · Principal investigator
  • Chongqing Cancer Hospital
    Chongqing, China
    Recruiting
    • Yongsheng Li · Contact
    • Yongsheng Li · Principal investigator
  • Chongqing Cancer Hospital
    Chongqing, China
    Recruiting
    • Hong Luo · Contact
    • Hong Luo · Principal investigator
  • The First Affiliated Hospital of Chongqing Medical University
    Chongqing, China
    Recruiting
    • Chengyou Du · Contact
    • Chengyou Du · Principal investigator
  • The Southwest Hospital of AMU
    Chongqing, China
    Recruiting
    • Zhiqing Liang · Contact
    • Zhiqing Liang · Principal investigator
  • Fujian Cancer Hospital
    Fuzhou, China
    Recruiting
    • An Lin · Contact
    • An An · Principal investigator
  • Fujian Cancer Hospital
    Fuzhou, China
    Recruiting
    • Yu Chen · Contact
    • Yu Chen · Principal investigator
  • Zhejiang Provincial People's Hospital
    Hangzhou, China
    Recruiting
    • Zhiquan Qin · Contact
    • Zhiquan Qin · Principal investigator
  • Harbin Medical University Cancer Hospital
    Harbin, China
    Recruiting
    • Baogang Liu · Contact
    • Baogang Liu · Principal investigator
  • Anhui Provincial Hospital
    Hefei, China
    Recruiting
    • Yueyin pan · Contact
    • Yueyin pan · Principal investigator
  • Linyi Cancer Hospital
    Linyi, China
    Recruiting
    • Jingfen Wang · Contact
    • Zhen Wang · Principal investigator
  • Jiangsu Province Hospital
    Nanjing, China
    Recruiting
    • Yongmei Yin · Contact
    • Yongmei Yin · Principal investigator
  • Jiangsu Province Hospital
    Nanjing, China
    Recruiting
    • Zengjun Wang · Contact
    • Zengjun Wang · Principal investigator
  • Shanghai Orient Hospital
    Shanghai, China
    Recruiting
  • Shanghai Sixth People's Hospital
    Shanghai, China
    Recruiting
    • Hun Zhao · Contact
    • Hun Zhao · Principal investigator
  • Shengjing Hospital of China Medical University
    Shengjing, China
    Recruiting
    • Bin Wu · Contact
    • Bin Wu · Principal investigator
  • Liaoning Cancer Hospital
    Shenyang, China
    Recruiting
    • Chunyan Wang · Contact
    • Chunyan Wang · Principal investigator
  • The First Hospital of China Medical University
    Shenyang, China
    Recruiting
    • Funan Liu · Contact
    • Funan Liu · Principal investigator
  • The People's Hospital of Liaoning Province
    Shenyang, China
    Recruiting
    • Lijie He · Contact
    • Lijie He · Principal investigator
  • The Fourth Hospital of Hebei Medical University
    Shijiazhuang, China
    Recruiting
    • Da Jiang · Contact
    • Da Jiang · Principal investigator
  • Shanxi Bethune Hospital
    Taiyuan, China
    Recruiting
    • Huijing Feng · Contact
    • Huijing Feng · Principal investigator
  • Shanxi Provincial Cancer Hospital
    Taiyuan, China
    Recruiting
    • Yusheng Wang · Contact
    • Yusheng Wang · Principal investigator
  • Shanxi Provincial Cancer Hospital
    Taiyuan, China
    Recruiting
    • Shuqing Wei · Contact
    • Shuqing Wei · Principal investigator
  • Taizhou Hospital of Zhejiang Province
    Taizhou, China
    Recruiting
    • Dongqing Lv · Contact
    • Dongqing Lv · Principal investigator
  • The Second Hospital of Tianjin Medical University
    Tianjin, China
    Recruiting
    • Gang Li · Contact
    • Gang Li · Principal investigator
  • Hubei Cancer Hospital
    Wuhan, China
    Recruiting
    • Feng Zhang · Contact
    • Feng Zhang · Principal investigator
  • Hubei Cancer Hospital
    Wuhan, China
    Recruiting
    • Yi Huang · Contact
    • Yi Huang · Principal investigator
  • Union Hospital Tongji Medical College Huazhong University of Science and Technology
    Wuhan, China
    Recruiting
    • Guiling Li · Contact
    • Guiling Li · Principal investigator
  • The First Affiliated Hospital of Xi'an Jiaotong University
    Xi'an, China
    Recruiting
    • Ruifang An · Contact
    • Ruifang An · Principal investigator
  • Xi 'an International Medical Center Hospital
    Xi'an, China
    Recruiting
    • Xinpeng Han · Contact
    • Xinpeng Han · Principal investigator
  • Xi 'an International Medical Center Hospital
    Xi'an, China
    Recruiting
    • Kejun Nan · Contact
    • Kejun Nan · Principal investigator
  • Yantai Yuhuangding Hospital
    Yantai, China
    Recruiting
    • Jitao Wu · Contact
    • Jitao Wu · Principal investigator
  • Yibin Second People's Hospital
    Yibin, China
    Recruiting
    • Kaijian Lei · Contact
    • Kaijian Lei · Principal investigator
  • Henan Cancer Hospital
    Zhengzhou, China
    Recruiting
    • Suxia Luo · Contact
    • Suxia Luo · Principal investigator
  • The first affilated hospital of zhengzhou university
    Zhengzhou, China
    Recruiting
    • Yanru Qin · Contact
    • Yanru Qin · Principal investigator
  • The first affilated hospital of zhengzhou university
    Zhengzhou, China
    Recruiting
    • Xingya Li · Contact
    • Xingya Li · Principal investigator
  • Zhujiang Hospital of Southern Medical University
    Zhujiang, China
    Recruiting
    • Jian Zhang · Contact
    • Jian Zhang · Principal investigator
08

References and documents

Individual participant data

Plan to share: Yes — The data will be published or presented for publications (poster, abstract, articles or papers) or any presentations.

Time frame: After the trial completed

Access criteria: NCI is committed to sharing data in accordance with NIH policy.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Mar 2021 (actual). Primary completion is estimated for Nov 2025, 56 months after the start.

Of 194 industry-sponsored phase 1/2 interventional studies under Neoplasms, half reached primary completion within 61 months of starting (the median), counting those still running; a quarter within 41 and three quarters within 88. This study's planned 56 months is close to that.

Counting every sponsor, half of 296 studies reached it within 60 months; a quarter within 39 and three quarters within 89.

Neoplasms covers many different conditions, not one, so the studies compared here vary widely. Read these figures as a rough guide.

How these figures are worked out, and which studies are left out of them.

Registered
May 30, 2023
First posted
Jun 26, 2023
StartActual
Mar 9, 2021
Primary completionEst.
Nov 30, 2025
CompletionEst.
Nov 30, 2025
Last update
Dec 5, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 5, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05918445
Lead sponsor
Biotheus Inc.
Responsible party
Sponsor
First posted
Jun 26, 2023
Start date
Mar 9, 2021
Primary completion
Nov 30, 2025 (estimated)
Completion
Nov 30, 2025 (estimated)
Last update
Dec 5, 2024

Study contacts

Ye Guo
Contact
pattrickguo@gmail.com
135 0167 8472
Ye Guo
principal investigator · Shanghai Orient Hospital

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Pumitamig

Start the discussion